Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 12:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 1,099 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Control Subjects Clear all

Conditions: Healthy Volunteers
Interventions: iCP-NI, Placebo; Drug
Lead sponsor: Cellivery Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Systemic Lupos Erythematosus, SLE
Interventions: BIIB068, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Healthy Subjects
Interventions: Netarsudil (AR-13324) Ophthalmic Solution, Netarsudil (AR-13324) Ophthalmic Solution Placebo; Drug
Lead sponsor: Aerie Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Bedminster, New Jersey

Conditions: SARS CoV-2
Interventions: GB-0669, Placebo; Drug
Lead sponsor: Generate Biomedicines; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Somerville, Massachusetts

Conditions: Atopic Dermatitis
Interventions: LEO 138559, LEO 138559 Placebo; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Exposure
Interventions: SP-333; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Alzheimer's Disease, Huntington's Disease
Interventions: Dimebon; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Glendale, California

Conditions: Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis
Interventions: Non-Interventional Study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 40 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy Subjects
Interventions: AC-076 for s.c. administration, Placebo; Drug
Lead sponsor: Viatris Innovation GmbH; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Thrombosis
Interventions: BMS-986141, Placebo, Aspirin, Itraconazole; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 148 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Cypress, California • Austin, Texas

Conditions: Dry Eye
Interventions: EBI-005-1, EBI-005-1 Placebo; Drug
Lead sponsor: Eleven Biotherapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy
Interventions: Intra-epidermal stimulation electrode; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 21 Years to 60 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Diabetes Mellitus
Interventions: JTT-251 or Placebo; Drug
Lead sponsor: Shionogi Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Bleeding
Interventions: Andexanet alfa, Apixaban, Rivaroxaban, Edoxaban, Placebo; Biological · Drug
Lead sponsor: Portola Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Cypress, California

Conditions: Healthy Volunteers, Pharmacokinetics of ASP015K
Interventions: ASP015K, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy
Interventions: BMS-986166, Placebo matching BMS-986166; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Cachexia
Interventions: GSK2881078, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Overland Park, Kansas • Baltimore, Maryland

Conditions: Parkinson's Disease
Interventions: Rasagiline, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 20 Years to 50 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Glendale, California

Conditions: Nicotine Vaping, Nicotine, Vaping
Interventions: CA35, CM35, Cig; Other
Lead sponsor: Philip Morris Products S.A.; Industry
Eligibility: 24 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Healthy Volunteers
Interventions: Placebo Comparator: Cohort 1 Placebo, 52364 3 mg, Placebo Comparator: Cohorts 2, 3, 4 & 5 Two subjects each arm will be assigned to receive placebo, 52364 10 mg, 52364 30 mg, 52364 100 mg, 52364 1 mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Hypoxia, Desaturation of Blood
Interventions: Non-Invasive Controlled Hypoxia; Device
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Louisville, Colorado

Conditions: Herpes Zoster, Varicella Zoster
Interventions: CRV 101, Placebo; Biological
Lead sponsor: Curevo Inc; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Vision
Interventions: Stendra 200 mg, Placebo; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Malaria, Prevention and Control, Acquired Immunity
Interventions: PfSPZ; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

iCP-NI - Safety, Tolerability, Pharmacokinetic, and Immunogenicity Study in Healthy Male and Female Subjects

A Phase 1, Single-Ascending-Dose, Safety, Tolerability, Pharmacokinetic(PK), and Pharmacodynamic(PD) Study of BIIB068 in Healthy Participants

A Controlled Study of the Aqueous Humor Dynamics of AR-13324 Ophthalmic Solution in Healthy Adult Volunteers

Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-0669 in Healthy Adult Participants

A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects

Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of SP-333 Tablets in Healthy Adult Subjects

A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects

Hematopoiesis in MBL and CLL Versus Healthy Age-Matched Control Subjects

A Study Conducted in Healthy Male Subjects to Investigate the Safety and Tolerability of AC-76, Its Fate in the Body, and Its Effect on the Body

Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects

Phase 1 Study for Safety and Tolerability of EBI-005 Topically Administered to Eyes of Healthy Adult Subjects

Intra-epidermal Stimulation (IES) of Small Nerve Fibers (A-delta Fibers)

Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects

A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K in Healthy Subjects

A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of GSK2881078 in Single and Repeat Doses

A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Rasagiline

Nicotine Pharmacokinetics Following Use of the P4M3 Gen 2.0 E-Cigarette Compared to Smoking Cigarettes

First Safety Study in Humans of a Single Dose of CPG 52364

SpO2 Accuracy Low Saturation Validation of the OxySoftN Sensor

Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects

Safety Study Looking at the Effects of Stendra on Vision

Experimental PfSPZ Vaccine in Adults Without Malaria